Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson K E
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Br J Pharmacol. 1999 Feb;126(3):819-25. doi: 10.1038/sj.bjp.0702358.
The possible existence of a beta3-adrenergic receptor (beta3-AR) in the human detrusor muscle was investigated by in vitro functional studies and analysis of mRNA expression. Isoprenaline, noradrenaline and adrenaline each produced a concentration-dependent relaxation of the human detrusor. The rank order for their relaxing potencies was isoprenaline (pD2 6.37+/-0.07) > or = noradrenaline (pD2 6.07+/-0.12) > or = adrenaline (pD2 5.88< or =0.11). Neither dobutamine (beta1- and beta2-AR agonist) nor procaterol (beta2-AR agonist) produced any significant relaxation at concentrations up to 10(-5) M. BRL37344A, CL316243 and CGP-12177A (beta3-AR agonists), relaxed the preparations significantly at concentrations higher than 10(-6) M. The pD2 values for BRL37344A, CL316243 and CGP-12177A were 6.42+/-0.25, 5.53+/-0.09 and 5.74+/-0.14, respectively. CGP-20712A (10(-7) - 10(-5) M), a beta1-AR antagonist, did not affect the isoprenaline-induced relaxation. On the other hand, ICI-118,551, a beta2-AR antagonist, produced a rightward parallel shift of the concentration-relaxation curve for isoprenaline only at the highest concentration used (10(-5) > M) and its pKB value was 5.71+/-0.19. Moreover, SR58894A (10(-7) - 10(-5) M), a beta3-AR antagonist, caused a rightward shift of the concentration-relaxation curve for isoprenaline in a concentration-dependent manner. The pA2 value and slope obtained from Schild plots were 6.24+/-0.20 and 0.68+/-0.31. The beta1-, beta2- and beta3-AR mRNAs were all positively expressed in detrusor smooth muscle preparations in a reverse transcription polymerase chain reaction assay. In conclusion, the present results provide the first evidence for the existence of the beta3-AR subtype in the human detrusor. They also suggest that the relaxation induced by adrenergic stimulation of the human detrusor is mediated mainly through beta3-AR activation.
通过体外功能研究和mRNA表达分析,对人逼尿肌中β3 - 肾上腺素能受体(β3 - AR)的可能存在情况进行了研究。异丙肾上腺素、去甲肾上腺素和肾上腺素均可使人类逼尿肌产生浓度依赖性舒张。它们的舒张效力顺序为:异丙肾上腺素(pD2 6.37±0.07)≥去甲肾上腺素(pD2 6.07±0.12)≥肾上腺素(pD2 5.88≤0.11)。多巴酚丁胺(β1 - 和β2 - AR激动剂)和丙卡特罗(β2 - AR激动剂)在浓度高达10⁻⁵ M时均未产生任何显著舒张作用。BRL37344A、CL316243和CGP - 12177A(β3 - AR激动剂)在浓度高于10⁻⁶ M时可使标本显著舒张。BRL37344A、CL316243和CGP - 12177A的pD2值分别为6.42±0.25、5.53±0.09和5.74±0.14。β1 - AR拮抗剂CGP - 20712A(10⁻⁷ - 10⁻⁵ M)不影响异丙肾上腺素诱导的舒张。另一方面,β2 - AR拮抗剂ICI - 118,551仅在所用最高浓度(10⁻⁵>M)时使异丙肾上腺素的浓度 - 舒张曲线向右平行移动,其pKB值为5.71±0.19。此外,β3 - AR拮抗剂SR58894A(10⁻⁷ - 10⁻⁵ M)使异丙肾上腺素的浓度 - 舒张曲线以浓度依赖性方式向右移动。从Schild图获得的pA2值和斜率分别为6.24±0.20和0.68±0.31。在逆转录聚合酶链反应分析中,β1 -、β2 - 和β3 - AR的mRNA在逼尿肌平滑肌标本中均呈阳性表达。总之,目前的结果为人类逼尿肌中存在β3 - AR亚型提供了首个证据。它们还表明,肾上腺素能刺激人类逼尿肌所诱导的舒张主要通过β3 - AR激活介导。